European Case Law Identifier: | ECLI:EP:BA:2002:T089000.20021028 | ||||||||
---|---|---|---|---|---|---|---|---|---|
Date of decision: | 28 October 2002 | ||||||||
Case number: | T 0890/00 | ||||||||
Application number: | 94920360.8 | ||||||||
IPC class: | A61K 9/16 | ||||||||
Language of proceedings: | EN | ||||||||
Distribution: | C | ||||||||
Download and more information: |
|
||||||||
Title of application: | Anti-angiogenic compositions and methods of use | ||||||||
Applicant name: | Angiotech Pharmaceuticals, Inc., et al | ||||||||
Opponent name: | (I) Schering AG (II) Focal, Inc. (III) Inflow Dynamics AG (IV) STS Biopolymers Inc. (V) Abbott Vascular Devices Limited |
||||||||
Board: | 3.3.02 | ||||||||
Headnote: | - | ||||||||
Relevant legal provisions: |
|
||||||||
Keywords: | Remittal to the first instance for further prosecution- New main request not examined for all EPC requirements Apportionment of costs (no): more appropriate for decision at end of further first instance proceedings |
||||||||
Catchwords: |
- |
||||||||
Cited decisions: |
|
||||||||
Citing decisions: |
|
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t000890eu1.html
Date retrieved: 17 May 2021